eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 3
Review paper

New directions in hepatitis B therapy research

Marta Lewandowska, Anna Piekarska

Clin Exp HEPATOL 2017; 3, 3: 119–126
Online publish date: 2017/07/05
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Chronic hepatitis B treatment is available for a long period, allowing disease control and infection suppression, but it is rarely responsible for HBsAg clearance. None of the drugs available aim at cccDNA, the obstacle in HBV infection eradication. Complications related to CHB, such as liver insufficiency, cirrhosis, and hepatocellular carcinoma are reduced in conditions of good viremia suppression, but still exist even after HBsAg seroclearance, what makes a need for urgent forthcoming of new therapeutics. Recent years brought promising and interesting results of experimental approaches, which are directed against different phases of HBV life cycle, target ccc DNA, or boost, and restore host immune response. Unfortunately, encouraging results in vitro and on animal models are not always reflected in human. Nevertheless, the multiplicity of novel antivirals allows to expect that at least some of them will enter clinical practice and relieve patients from chronic hepatitis B, fatal and devastating disease.

HBV life cycle, cccDNA silencing, novel HBV antivirals, immunotherapeutics

GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-
specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171.
Liang T, Block T, McMahon B. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 2015; 62: 1893-1908.
European Association For the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
Xia Y, Stadler D, Ko C, et al. Analyses of HBV cccDNA Quantification and Modification. Methods Mol Biol 2017; 1540: 59-72.
Chisari FV, Isogawa M, Wieland SF. Pathogenesis of Hepatitis B Virus Infection. Pathol Biol (Paris) 2010; 58: 258-266.
Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-1092.
Rollier CS, Reyes-Sandoval A, Cotthingam MG, et al. Viral vectors as vaccine platforms: deployment in sight. Curr Opinion Immunol 2011; 23: 377-382.
Martin P, Dubois C, Jacquier E, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 2015; 64: 1961-1971.
Cova L. Present and future DNA vaccines for chronic hepatitis B treatment. Expert Opin Biol Ther 2017; 17: 185-195.
Lok AS, Pan CQ, Han SH, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis. J Hepatol 2016; 65: 509-516.
Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343: 1221-1228.
Boni C, Fisicaro P, Valdatta C, et al. Characterization of Hepatitis B Virus (HBV)-Specific T-Cell. Dysfunction in Chronic HBV Infection. J Virol 2007; 81: 4215-4225.
Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
Cai G, Karni A, Oliveira EM, et al. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol 2004; 230: 89-98.
Sherman AC, Trehanpati N, Daucher M, et al. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir. AIDS Res Hum Retroviruses 2013; 29: 665-672.
Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74-86.
Barbalat R, Ewald SE, Mouchess ML, et al. Nucleic acid recognition by the innate immune system. Annu Rev Immunol 2011; 29: 185-214.
Lanford RE, Guerra B, Chavez D, et al. GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. Gastroenterology 2013; 144: 1508-1517.e10.
Lopatin U, Wolfgang G, Tumas D, et al. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir Ther 2013; 18: 409-418.
Laity JH, Lee BM, Wright PE. Zinc finger proteins: new insights into structural and functional. Diversity. Curr Opin Struct Biol 2001; 11: 39-46.
Zimmerman KA, Fischer KP, Joyce MA, et al. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol 2008; 82: 8013-8021.
Cradick TJ, Keck K, Bradshaw S, et al. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 2010; 18: 947-954.
Chen J, Zhang W, Lin J, et al. An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases. Mol Ther 2014; 22: 303-311.
Bloom K, Ely A, Mussolino C, et al. Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases. Mol Ther 2013; 21: 1889-1897.
Makarova KS, Haft DH, Barrangou R, et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 2011; 9: 467-477.
Lin SR, Yang HC, Kuo YT, et al. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates in Vivo. Mol Ther Nucleic Acids 2014; 3: e186.
Katen SP, Chirapu SR, Finn MG, et al. Trapping of Hepatitis B Virus capsid assembly intermediates by phenylpropanamide assembly accelerators. ACS Chem Biol 2010; 5: 1125-1136.
King RW, Ladner SK, Miller TJ, et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropanamide derivative, alone and in combination with (-)β-l-2’,3’-dideoxy-3’-thia­cytidine. Antimicrob Agents Chemother 1998; 42: 3179-3186.
Campagna MR, Liu F, Mao R, Mills C, Cai D, Guo F, Zhao X, Ye H, Cuconati A, Guo H, Chang J, Xu X, Block TM, Guo JT. Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol 2013; 87: 6931-6942.
Stray SJ, Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. Mol Recognit 2006; 19: 542-548.
Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014; 146: 1070-1083.
Blank A, Markert C, Hohmann N, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B. J Hepatol 2016; 65: 483-489.
Volz T, Allweiss L, Ben M’Barek M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: 861-867.
Rizzetto M, Smedile A. Pegylated interferon therapy of chronic hepatitis D: in need of revision. Hepatology 2015; 61: 1109-1111.
Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol 2016; 65: 490-498.
Ebert G, Poeck H, Lucifora J, et al. 5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology 2011; 141: 696-706.e3.
Giladi H, Ketzinel-Gilad M, Rivkin L, et al. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003; 8: 769-776.
Lanford R, Wooddell CI, Chavez D, et al. ARC-520 RNAi therapeutic reduces HBV DNA, s and e antigen in a chimpanzee with a very high biral titer. Hepatology 2013; 58: 707A.
Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther 2014; 19: 687-692.
Murakami E, Wang T, Park Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother 2015; 59: 3563-3569.
Gibson AK, Shah BM, Nambiar PH, et al. Tenofovir Alafenamide: A Review of Its Use in the Treatment of HIV-1 Infection. Ann Pharmacother 2016; 50: 942-952.
Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 2015; 62: 533-540.
Yuen MF, Lee SH, Kang HM, et al. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. Antimicrob Agents Chemother 2009; 53: 1779-1785.
Fung J, Lai CL, Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis. Expert Opin Investig Drugs 2008; 17: 1581-1588.
Yuen MF, Kim J, Kim CR, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther 2006; 11: 977-983.
Lai CL, Ahn SH, Lee KS, et al. Phase IIb multicentred randomized trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 2014; 63: 996-1004.
Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997; 176: 1517-1523.
Yuen MF, Han KH, Um SH, et. al. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B
patients with lamivudine-resistant disease. Hepatology 2010; 51: 767-776.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe